Skip to main content

Merck, Portola to collaborate to develop stroke treatment


WHITEHOUSE STATION, N.J. Two drug companies have announced an exclusive global collaboration and license agreement on an investigational stroke drug.

Merck & Co. and Portola Pharmaceuticals said they would work to develop and commercialize betrixaban, an anticoagulant drug in phase 2 trials as a prevention of stroke in patients with atrial fibrillation.

Merck will pay Portola an initial fee of $50 million for an exclusive worldwide license to betrixaban, and Portola is eligible to receive milestone payments of up to $420 million and royalties on worldwide sales of the drug if it obtains approval. Merck will also assume all development and commercialization costs, including the costs of phase 3 trials. Portola has retained an option to co-fund phase 3 trials in return for additional royalties and to co-promote betrixaban with Merck in the United States.

This ad will auto-close in 10 seconds